Accueil / Communiqués / VALBIOTIS Obtains the European Patent for VALEDIA®

VALBIOTIS Obtains the European Patent for VALEDIA®

Monday, February 11th 2019 at 4:40pm UTC

• Guaranteed exclusivity on the prediabetes and metabolic diseases
market in 38 countries across Europe, including the European Union.

• VALEDIA® now holds industrial property
rights for the two major global markets: Europe and the United States.

• An important milestone for establishing a commercial partnership
with a major player in the healthcare sector.

LA ROCHELLE, France–(BUSINESS WIRE)– Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a
French Research & Development company committed to scientific innovation
for preventing and combating metabolic diseases
, announces the
obtention of the European patent for TOTUM-63.1 This patent
directly covers the active substance of VALEDIA® for use in
38 European countries on the prediabetes and metabolic diseases market,
including type 2 diabetes and NAFLD. After obtaining the US patent in
2018, VALBIOTIS’ industrial property for VALEDIA® is now
protected on its two main global markets (Europe and the United States).
These markets have similar-sized prediabetic populations, each of which
exceeds 80 million people.2,3

« This European recognition of VALEDIA® is
a significant milestone in accessing the prediabetes market in Europe.
After obtaining the patent in the United States last year, VALBIOTIS now
has guaranteed exclusivity for VALEDIA
® on the
two major global prediabetes markets, on both sides of the Atlantic.
This will be a crucial asset for securing future partnerships with
players in the healthcare sector; it paves the way for an expected
commercial success for VALEDIA
®. Furthermore,
this favorable decision validates our expertise in terms of developing
innovative and patentable plant-based active substance, for preventing
and combating metabolic diseases
« , comments Sébastien PELTIER, CEO
of VALBIOTIS.

This patent, obtained in less than 3 years, guarantees exclusive
exploitation rights of VALEDIA® until 2035 in Europe,
including the 28 countries of the European Union. In line with the
American patent that had already been obtained, this patent grants
protection over extensive claims, in particular, the exact composition
of the active substance (plant extracts and biomolecules), the possible
combinations with other products or substances, and most importantly,
the specific application of this innovation in the field of metabolic
diseases.

The TOTUM-63 patent is co-owned with the CNRS (French National Center
for Scientific Research), Clermont Auvergne University and La Rochelle
University, long-standing academic partners of VALBIOTIS since its
creation in 2014. The strategic plan is to register the patent globally
in more than 60 countries, including European and North American
territories. It has already been granted and registered in France, the
United States, and South Africa.

About TOTUM-63, the main active ingredient of VALEDIA®

TOTUM-63 is based on a specific and patented combination of 5 plant
extracts selected for their effects on the metabolism. It acts on
various pathophysiological targets of type 2 diabetes to reduce the
clinical risk factors of the disease.

This first-in-class product has been developed to introduce a new
perspective into prediabetes management and to help pre-diabetic people
live healthy lives.

ABOUT VALBIOTIS

VALBIOTIS is a French Research & Development company committed to
scientific innovation for the treatment and prevention of metabolic
diseases. Its products are made for major players in the healthcare
sector. VALBIOTIS particularly focuses on solutions to prevent type 2
diabetes, NASH (nonalcoholic steatohepatitis), obesity and
cardiovascular diseases.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed
numerous partnerships with top academic centers in France and abroad,
including La Rochelle University, the CNRS and Clermont Auvergne
University located in Clermont-Ferrand. These partnerships have enabled
VALBIOTIS to benefit from strong financial leverage, particularly thanks
to experts and technical partners who support its projects. The Company
has established three sites in France – Périgny, La Rochelle (17) and
Riom (63) – and an American office in Boston (MA).

VALBIOTIS is a member of the « BPI Excellence » network and received the
« Innovative Company » status accorded by BPI France. Valbiotis has also
been awarded « Young Innovative Company » status and has received major
financial support from the European Union for its research programs by
obtaining support from the European Regional Development Fund (ERDF).
VALBIOTIS is PEA/SME eligible.

Find out more about VALBIOTIS:
www.valbiotis.com/

Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL

WARNING

This press release contains forward-looking statements concerning the
objectives of VALBIOTIS. VALBIOTIS considers that these projections are
based on information currently available by VALBIOTIS and on reasonable
assumptions.

However, there can be no assurance that the estimates contained in such
forward-looking statements will be verified, which estimates are subject
to numerous risks including the risks set forth in the reference
document of VALBIOTIS filed with the French Financial Markets Authority
(Autorite? des Marche?s Financiers) under number I.17-012 on April 5,
2017 as well as in its 2017 annual financial report filed with the
French Financial Markets Authority on April 3, 2018. These documents are
available on the Company’s website (www.valbiotis.com).

VALBIOTIS declines all responsibility for updating or revising these
forward-looking statements. This press release and the information that
it contains do not constitute an offer to sell or subscribe for, or a
solicitation of an offer to purchase or subscribe for, VALBIOTIS shares
in any country.

1 « A composition comprising a mixture of plant extracts, or a
mixture of the molecules contained in these plants, used to target
carbohydrate and/or lipid metabolism », application no.: EP 15801895.2.
2
Eades C. et al., Prevalence of impaired glucose regulation in
Europe: a meta-analysis, The European Journal of Public Health, Vol. 26,
No. 4, 699–706, 2016.
3 Center for Disease Control and
Prevention, July 2018, www.cdc.gov/features/prediabetes-awareness-campaign/index.html

Contacts

VALBIOTIS
CORPORATE COMMUNICATION
Carole Rocher /
Marc
Delaunay
+33 5 46 28 62 58
medias@valbiotis.com

FINANCIAL COMMUNICATION
ACTIFIN
Stéphane Ruiz
+33 1 56 88
11 14
sruiz@actifin.fr

MEDIA RELATIONS
MADIS PHILEO
Guillaume De Chamisso
+33 6
85 91 32 56
guillaume.dechamisso@madisphileo.com

UNITED STATES
SOLEBURY TROUT
Rebecca John / Patrick Till
+1
646 378 2935
rjohn@troutgroup.com
ptill@troutgroup.com

Source: VALBIOTIS


Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …